/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...

Related Keywords

United States , Spain , Barcelona , Comunidad Autonoma De Cataluna , Switzerland , America , Kevin Garey , Eugenie Basseres , Davidp Luci , Company Ph , Society Or Healthcare Epidemiology Of America , Global European Society Of Clinical Microbiology , Trial Oversight Committee , Data Monitoring Committee , Exchange Commission On Form , Infectious Diseases Society Of America , European Society Of Clinical Microbiology , Research Scientist , Acurx Pharmaceuticals , Nasdaq , Acurx Pharmaceuticals Inc , Company Scientific Advisory Board , University Of Houston College Pharmacy , Drug Administration , Exchange Commission , Prnewswire Acurx Pharmaceuticals Inc , European Society , Clinical Microbiology , Infectious Diseases , Houston College , Principal Investigator , Acurx Scientific Advisory Board , Double Blind Study , Ibezapolstat Compared , Executive Committee , Ibezapolstat Phase , Scientific Advisory Board , Clinical Cure , Modified Intent , Treat Population , Per Protocol Population , Prescribing Information , Independent Data Monitoring Committee , Gram Positive Selective Spectrum , Qualified Infectious Disease Product , Generating New Antibiotic Incentives Now , Clinical Practice Guidelines , Infectious Diseases Society , Healthcare Epidemiology , New England Journal , Bile Acid , Private Securities Litigation Reform Act , Nc ,